<code id='BFAC87EF62'></code><style id='BFAC87EF62'></style>
    • <acronym id='BFAC87EF62'></acronym>
      <center id='BFAC87EF62'><center id='BFAC87EF62'><tfoot id='BFAC87EF62'></tfoot></center><abbr id='BFAC87EF62'><dir id='BFAC87EF62'><tfoot id='BFAC87EF62'></tfoot><noframes id='BFAC87EF62'>

    • <optgroup id='BFAC87EF62'><strike id='BFAC87EF62'><sup id='BFAC87EF62'></sup></strike><code id='BFAC87EF62'></code></optgroup>
        1. <b id='BFAC87EF62'><label id='BFAC87EF62'><select id='BFAC87EF62'><dt id='BFAC87EF62'><span id='BFAC87EF62'></span></dt></select></label></b><u id='BFAC87EF62'></u>
          <i id='BFAC87EF62'><strike id='BFAC87EF62'><tt id='BFAC87EF62'><pre id='BFAC87EF62'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:494
          Dr. Laurie Glimcher, CEO of Dana Farber Cancer Institute, opens both arms while talking — coverage from STAT
          Laurie Glimcher, CEO of Dana Farber Cancer Institute, is the architect of the biggest shakeup in Boston health care in decades. David L. Ryan/Globe Staff

          Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.

          The younger Glimcher took that advice to heart. In the late 1990s at her Harvard immunology lab, Glimcher and her postdoctoral student began a series of experiments that colleagues deemed “crazy.” But after a year of trial and error, the lab had a eureka moment when it found that white blood cells could be reprogrammed, a seminal discovery that led to new ways to treat cancer.

          advertisement

          “Most scientists do good work, but they don’t transform a scientific question,” said Glimcher. “I always felt the only way to do that is to think big and go after something that’s going to be really important.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Stanford president to resign after investigation of research
          Stanford president to resign after investigation of research

          StanfordpresidentandneuroscientistMarcTessier-LavignePhotoillustration:AlexHogan/STAT;photo:GettyIma

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Sanofi CEO defends move to abandon profit guidance, boost research

          SanofiCEOPaulHudsonCarolynKaster/APLONDON—SanofiCEOPaulHudsononWednesdaydefendedhiscompany’srecentmo